3 September 2024 ORYZON continues to strengthen its patent portfolio for vafidemstat with additional “Decision to grant” communications
25-26 September 2024 Sachs Annual Biotech in Europe Forum 2024 Mövenpick Hotel Basel Basel Switzerland
21-24 September 2024 European College of Neuropsychopharmacology (ECNP) congress 2024 Allianz MiCo convention center, Milan MI Italy
31 July 2024 ORYZON reports financial results and corporate update for half-year ending June 30, 2024
26 June 2024 ORYZON announces presentation of final data from PORTICO, vafidemstat’s global Phase IIb trial in Borderline Personality Disorder, at the 37th ECNP annual conference
14 June 2024 ORYZON presents preliminary data from ongoing Phase Ib FRIDA trial with iadademstat plus gilteritinib in relapsed/refractory FLT3-mut AML patients at EHA-2024